Page last updated: 2024-08-24

ibandronic acid and Hangman Fracture

ibandronic acid has been researched along with Hangman Fracture in 34 studies

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (44.12)29.6817
2010's13 (38.24)24.3611
2020's6 (17.65)2.80

Authors

AuthorsStudies
Dong, S; Hu, Y; Ke, Z; Lv, M; Shen, J; Song, L; Wu, K; Xu, K; Yuan, Y1
Huang, J; Li, P; Li, Y; Wu, X1
Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T2
Bonel, H; Everts-Graber, J; Gahl, B; Häuselmann, H; Lehmann, D; Lehmann, T; Reichenbach, S; Studer, U; Ziswiler, HR1
Chen, LH; Ma, WJ; Wang, WY; You, RX1
Hagino, H; Hashimoto, J; Ito, M; Mizunuma, H; Nakamura, T; Nakano, T; Tobinai, M1
Barr, C; Day, BM; Felsenberg, D; Harris, S; Masanauskaite, D; Miller, PD; Recker, RR; Reginster, J; Silverman, S1
Ohashi, S; Ono, K; Tanaka, S1
Shiraishi, A1
Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S1
Reid, IR1
Hashimoto, J; Nakamura, T; Nakano, T; Tobinai, M; Yamamoto, M; Yoshida, S1
Hashimoto, J; Ito, M; Nakamura, T; Tobinai, M; Yoshida, S1
Keating, GM1
Hochberg, MC1
Dimai, HP; Dobnig, H; Fahrleitner-Pammer, A; Hauge, E; Obermayer-Pietsch, BM; Pieber, TR; Pilz, S; Piswanger-Soelkner, JC; Portugaller, RH; Prenner, G; Tscheliessnigg, KH1
Adami, S; Delmas, PD; Huss, H; Miller, PD; Patel, KM; Recker, RR; Schimmer, RC1
Tobinai, M1
Boyer, KM; Esses, SI; Finkelstein, J; Goldberg, MJ; Hitchcock, K; Jenkins, J; Keith, M; McGuire, R; Sluka, P; Turkelson, CM; Watters, WC; Wies, JL; Woodard, E1
Adler, G; Herdt, K; Klaus, J; Reinshagen, M; von Boyen, GB; von Tirpitz, C1
Dorst, A; Faber, H; Ibach, K; Preuss, J; Ringe, JD1
Dorst, A; Faber, H; Ibach, K; Ringe, JD; Sorenson, F1
Kuwahara, T; Suzuki, M; Tanaka, Y; Yamada, T1
Chesnut, CH; Christiansen, C; Delmas, PD; Emkey, R; Gilbride, J; Recker, RR; Schimmer, RC; Skag, A; Stakkestad, JA1
Chesnut, CH; Christiansen, C; Delmas, PD; Felsenberg, D; Gilbride, J; Hoiseth, A; Huss, H; Recker, R; Schimmer, RC; Skag, A; Stakkestad, JA1
Wallace, DJ1
Baylink, DJ; Chesnut, CH; Emkey, R; Ettinger, MP; Harris, ST; Miller, PD; Recker, RR; Schimmer, RC; Wasnich, RD; Watts, NB1
Adami, S; Bolognese, MA; Bonvoisin, B; Civitelli, R; Cooper, C; Delmas, PD; Dumont, E; Felsenberg, D; Kendler, DL; McClung, MR; Miller, PD; Recker, RR; Reginster, JY; Stakkestad, JA1
Bolognese, MA; Bonvoisin, B; Cooper, C; Delmas, PD; Felsenberg, D; Hughes, C; Kendler, DL; Lewiecki, EM; Luckey, M; Macovei, L; Mairon, N; McClung, MR; Miller, PD; Recker, RR; Reginster, JY; Stakkestad, JA1
Armbrecht, G; Felsenberg, D; Miller, P; Papapoulos, SE; Schimmer, RC; Wilson, K1
Fassbender, WJ; Stumpf, UC1
Hashimoto, J; Oshima, H; Tanaka, I1

Reviews

16 review(s) available for ibandronic acid and Hangman Fracture

ArticleYear
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
    Medical science monitor : international medical journal of experimental and clinical research, 2022, Apr-17, Volume: 28

    Topics: Bone Density; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures

2022
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
    Clinical and investigative medicine. Medecine clinique et experimentale, 2022, 09-21, Volume: 45, Issue:3

    Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Male; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Spinal Fractures; Zoledronic Acid

2022
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
    Archives of osteoporosis, 2023, 01-10, Volume: 18, Issue:1

    Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid

2023
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
    Calcified tissue international, 2023, Volume: 112, Issue:6

    Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome

2023
Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:17

    Topics: Denosumab; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures; Teriparatide; Zoledronic Acid

2023
Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014, Volume: 25, Issue:1

    Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Europe; Female; Follow-Up Studies; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Spinal Fractures; United States

2014
[Anti-osteoporosis drugs based on the guidelines for the Prevention and Treatment of Osteoporosis (2011 edition) ].
    Clinical calcium, 2014, Volume: 24, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cholecalciferol; Denosumab; Diphosphonates; Drug Therapy, Combination; Fractures, Spontaneous; Humans; Ibandronic Acid; Molecular Targeted Therapy; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide

2014
[Pharmacological profile and clinical evidence in patients with primary osteoporosis treated with intravenous ibandronate].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2014, Volume: 143, Issue:6

    Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Diphosphonates; Disease Models, Animal; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Durapatite; Haplorhini; Humans; Ibandronic Acid; Infusions, Intravenous; Osteoporosis; Randomized Controlled Trials as Topic; Rats; Spinal Fractures

2014
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
    Journal of endocrinological investigation, 2014, Volume: 37, Issue:8

    Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Ibandronic Acid; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Therapeutic Equivalency

2014
Ibandronate: A Review in Japanese Patients with Osteoporosis.
    Drugs & aging, 2016, Volume: 33, Issue:4

    Topics: Administration, Intravenous; Administration, Oral; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Japan; Lumbar Vertebrae; Osteoporosis; Risedronic Acid; Spinal Fractures

2016
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
    Current osteoporosis reports, 2008, Volume: 6, Issue:3

    Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid

2008
[Ibandronate].
    Clinical calcium, 2011, Volume: 21, Issue:1

    Topics: Administration, Oral; Bone Density Conservation Agents; Clinical Trials, Phase II as Topic; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Osteoporosis; Randomized Controlled Trials as Topic; Spinal Fractures

2011
[Ibandronate].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2

    Topics: Animals; Bone Density; Bone Resorption; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Ibandronic Acid; Osteoclasts; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic; Spinal Fractures

2004
Rapid prevention of vertebral fractures associated with osteoporosis.
    Orthopedics, 2005, Volume: 28, Issue:3

    Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogens; Female; Glucocorticoids; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risk Factors; Spinal Fractures; Treatment Outcome; Zoledronic Acid

2005
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, Volume: 17, Issue:2

    Topics: Administration, Oral; Animals; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase I as Topic; Diphosphonates; Dogs; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic; Rats; Spinal Fractures

2006
[New bone density conservation agents for osteoporosis under research and development: Ibandronate].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9

    Topics: Administration, Oral; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dosage Forms; Double-Blind Method; Drug Administration Schedule; Drug Design; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis; Randomized Controlled Trials as Topic; Research; Spinal Fractures

2007

Trials

13 trial(s) available for ibandronic acid and Hangman Fracture

ArticleYear
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
    Calcified tissue international, 2013, Volume: 93, Issue:2

    Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Infusions, Intravenous; Japan; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Risedronic Acid; Spinal Fractures; Time Factors; Treatment Outcome

2013
Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study.
    Journal of bone and mineral metabolism, 2016, Volume: 34, Issue:6

    Topics: Administration, Intravenous; Administration, Oral; Aged; Bone Density; Collagen Type I; Creatinine; Diphosphonates; Double-Blind Method; Female; Femur; Humans; Ibandronic Acid; Kidney Function Tests; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Peptides; Risedronic Acid; Spinal Fractures; Vitamin D

2016
Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.
    Journal of bone and mineral metabolism, 2017, Volume: 35, Issue:1

    Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Diphosphonates; Female; Femoral Neck Fractures; Femur Neck; Humans; Ibandronic Acid; Japan; Male; Middle Aged; Osteoporosis; Risedronic Acid; Spinal Fractures; Spine

2017
Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2009, Volume: 24, Issue:7

    Topics: Acid Phosphatase; Adult; Antacids; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Calcium Carbonate; Cholecalciferol; Collagen Type I; Diphosphonates; Double-Blind Method; Heart Transplantation; Humans; Ibandronic Acid; Isoenzymes; Lumbar Vertebrae; Male; Middle Aged; Radiography; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Time Factors; Transplantation, Homologous

2009
Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
    Calcified tissue international, 2010, Volume: 87, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Joint; Humans; Ibandronic Acid; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Radiography; Spinal Fractures

2010
Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.
    Journal of gastrointestinal and liver diseases : JGLD, 2011, Volume: 20, Issue:2

    Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Calcium Citrate; Cholecalciferol; Crohn Disease; Delayed-Action Preparations; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Ibandronic Acid; Incidence; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Prevalence; Sodium Fluoride; Spinal Fractures; Treatment Outcome; Young Adult

2011
Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
    Rheumatology (Oxford, England), 2003, Volume: 42, Issue:6

    Topics: Aged; Back Pain; Bone Density; Calcaneus; Diphosphonates; Drug Administration Schedule; Female; Femur Neck; Glucocorticoids; Humans; Hydroxycholecalciferols; Ibandronic Acid; Injections, Intravenous; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Prospective Studies; Spinal Fractures

2003
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2003, Volume: 14, Issue:10

    Topics: Aged; Back Pain; Body Height; Bone Density; Diphosphonates; Drug Administration Schedule; Female; Glucocorticoids; Humans; Hydroxycholecalciferols; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Spinal Fractures

2003
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2004, Volume: 15, Issue:10

    Topics: Administration, Oral; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Resorption; Collagen; Collagen Type I; Creatinine; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Hip; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteocalcin; Peptides; Risk Factors; Spinal Fractures; Treatment Outcome

2004
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:8

    Topics: Aged; Body Height; Bone and Bones; Bone Density; Diphosphonates; Double-Blind Method; Female; Femur; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Pelvic Bones; Prospective Studies; Risk Factors; Spinal Fractures; Treatment Outcome

2004
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
    Current medical research and opinion, 2005, Volume: 21, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Resorption; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Europe; Female; Humans; Ibandronic Acid; Middle Aged; North America; Osteoporosis; Postmenopause; Spinal Fractures; White People

2005
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005, Volume: 20, Issue:8

    Topics: Absorptiometry, Photon; Administration, Oral; Aged; Bone Density; Collagen; Collagen Type I; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Risk Factors; Spinal Fractures; Spine; Treatment Outcome

2005
Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
    Bone, 2005, Volume: 37, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Female; Humans; Ibandronic Acid; Incidence; Internationality; Lumbar Vertebrae; Middle Aged; North America; Osteoporosis, Postmenopausal; Risk; Severity of Illness Index; Spinal Fractures; Time Factors

2005

Other Studies

5 other study(ies) available for ibandronic acid and Hangman Fracture

ArticleYear
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2023, Volume: 34, Issue:11

    Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Registries; Spinal Fractures; Zoledronic Acid

2023
Efficacy, effectiveness and side effects of medications used to prevent fractures.
    Journal of internal medicine, 2015, Volume: 277, Issue:6

    Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid

2015
The treatment of symptomatic osteoporotic spinal compression fractures.
    The Journal of the American Academy of Orthopaedic Surgeons, 2011, Volume: 19, Issue:3

    Topics: Bone Density Conservation Agents; Calcitonin; Combined Modality Therapy; Diphosphonates; Evidence-Based Medicine; Fractures, Compression; Humans; Ibandronic Acid; Nerve Block; Organometallic Compounds; Osteoporotic Fractures; Pain Measurement; Spinal Fractures; Thiophenes; Vertebroplasty

2011
Ibandronate (Boniva): a new oral bisphosphonate.
    The Medical letter on drugs and therapeutics, 2005, Apr-25, Volume: 47, Issue:1207

    Topics: Administration, Oral; Diphosphonates; Dose-Response Relationship, Drug; Ibandronic Acid; Scleritis; Spinal Fractures; Spinal Injuries; Uveitis

2005
[DVO guideline 2006. What changes have there been in the diagnosis, prevention and treatment of osteoporosis?].
    Zeitschrift fur Rheumatologie, 2006, Volume: 65, Issue:5

    Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Male; Middle Aged; Minimally Invasive Surgical Procedures; Organometallic Compounds; Osteoporosis; Parathyroid Hormone; Peptide Fragments; Recombinant Proteins; Spinal Fractures; Teriparatide; Thiophenes

2006